Compare Abeona Therapeutics Inc (ABEO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Royal Caribbean Cruises Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Royal Caribbean Cruises Ltd trades at $281.14 (market cap $75.70B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 202.8× Abeona Therapeutics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RCL | |
|---|---|---|
Market Cap | $373.32M | $75.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $365.84 |
52-Week Low | $4.17 | $246.71 |
Enterprise Value | $228.22M | $96.98B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Royal Caribbean (RCL) trades at $282.26, down 4.74% on the day, showing bearish technical momentum but maintaining strong fundamentals. The company reported robust Q1 2026 earnings of $3.60 per share, beating expectations, with revenue growth accelerating from $16.5B in 2024 to $17.9B in 2025. Analyst consensus remains positive with a $325.10 price target, though technical indicators signal near-term caution with support at $283.
RCL presents a compelling investment case with strong profitability (50.41% ROE) and consistent earnings beats, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current pullback near key support levels offers potential entry points for long-term investors seeking exposure to the recovering cruise industry with disciplined financial management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
